BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30389925)

  • 1. Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer.
    Caetano MS; Hassane M; Van HT; Bugarin E; Cumpian AM; McDowell CL; Cavazos CG; Zhang H; Deng S; Diao L; Wang J; Evans SE; Behrens C; Wistuba II; Fuqua SAW; Lin H; Stabile LP; Watowich SS; Kadara H; Moghaddam SJ
    Nat Commun; 2018 Nov; 9(1):4589. PubMed ID: 30389925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.
    Caetano MS; Zhang H; Cumpian AM; Gong L; Unver N; Ostrin EJ; Daliri S; Chang SH; Ochoa CE; Hanash S; Behrens C; Wistuba II; Sternberg C; Kadara H; Ferreira CG; Watowich SS; Moghaddam SJ
    Cancer Res; 2016 Jun; 76(11):3189-99. PubMed ID: 27197187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interplay between estrogen and Stat3/NF-κB-driven immunomodulation in lung cancer.
    Deng S; Ramos-Castaneda M; Velasco WV; Clowers MJ; Gutierrez BA; Noble O; Dong Y; Zarghooni M; Alvarado L; Caetano MS; Yang S; Ostrin EJ; Behrens C; Wistuba II; Stabile LP; Kadara H; Watowich SS; Moghaddam SJ
    Carcinogenesis; 2020 Nov; 41(11):1529-1542. PubMed ID: 32603404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer.
    Qu Z; Sun F; Zhou J; Li L; Shapiro SD; Xiao G
    Cancer Res; 2015 Aug; 75(16):3209-15. PubMed ID: 26122841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL22 Promotes
    Khosravi N; Caetano MS; Cumpian AM; Unver N; De la Garza Ramos C; Noble O; Daliri S; Hernandez BJ; Gutierrez BA; Evans SE; Hanash S; Alekseev AM; Yang Y; Chang SH; Nurieva R; Kadara H; Chen J; Ostrin EJ; Moghaddam SJ
    Cancer Immunol Res; 2018 Jul; 6(7):788-797. PubMed ID: 29764837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer.
    Yuan B; Clowers MJ; Velasco WV; Peng S; Peng Q; Shi Y; Ramos-Castaneda M; Zarghooni M; Yang S; Babcock RL; Chang SH; Heymach JV; Zhang J; Ostrin EJ; Watowich SS; Kadara H; Moghaddam SJ
    JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35471938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential roles of STAT3 in the initiation and growth of lung cancer.
    Zhou J; Qu Z; Yan S; Sun F; Whitsett JA; Shapiro SD; Xiao G
    Oncogene; 2015 Jul; 34(29):3804-3814. PubMed ID: 25284582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
    Ohm AM; Tan AC; Heasley LE; Reyland ME
    Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. K-ras p21 expression and activity in lung and lung tumors.
    Ramakrishna G; Sithanandam G; Cheng RY; Fornwald LW; Smith GT; Diwan BA; Anderson LM
    Exp Lung Res; 2000 Dec; 26(8):659-71. PubMed ID: 11195463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
    Sato M; Vaughan MB; Girard L; Peyton M; Lee W; Shames DS; Ramirez RD; Sunaga N; Gazdar AF; Shay JW; Minna JD
    Cancer Res; 2006 Feb; 66(4):2116-28. PubMed ID: 16489012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K-ras mutation promotes ionizing radiation-induced invasion and migration of lung cancer in part via the Cathepsin L/CUX1 pathway.
    Wang L; Zhao Y; Xiong Y; Wang W; Fei Y; Tan C; Liang Z
    Exp Cell Res; 2018 Jan; 362(2):424-435. PubMed ID: 29246726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis.
    D'Amico S; Shi J; Martin BL; Crawford HC; Petrenko O; Reich NC
    Genes Dev; 2018 Sep; 32(17-18):1175-1187. PubMed ID: 30135074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of Tobacco Carcinogen-Induced Lung Tumor Development by a Novel STAT3 Decoy Inhibitor.
    Njatcha C; Farooqui M; Almotlak AA; Siegfried JM
    Cancer Prev Res (Phila); 2020 Sep; 13(9):735-746. PubMed ID: 32655003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation.
    Lei Y; Liu L; Zhang S; Guo S; Li X; Wang J; Su B; Fang Y; Chen X; Ke H; Tao W
    Mol Cancer; 2017 Nov; 16(1):170. PubMed ID: 29126425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of cyclooxygenase-2 inhibits K-ras-induced lung carcinogenesis.
    Pan Y; Jiang Y; Tan L; Ravoori MK; Gagea M; Kundra V; Fischer SM; Yang P
    Oncotarget; 2015 Nov; 6(36):38816-26. PubMed ID: 26452035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.
    Rabi T; Catapano CV
    Tumour Biol; 2016 Sep; 37(9):12455-12464. PubMed ID: 27333990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis.
    Schmidt ML; Hobbing KR; Donninger H; Clark GJ
    Cancer Res; 2018 May; 78(10):2614-2623. PubMed ID: 29735543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways.
    Meng J; Zhang XT; Liu XL; Fan L; Li C; Sun Y; Liang XH; Wang JB; Mei QB; Zhang F; Zhang T
    Cell Signal; 2016 Nov; 28(11):1673-82. PubMed ID: 27449264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.
    Clay TD; Russell PA; Do H; Sundararajan V; Conron M; Wright GM; Solomon B; Dobrovic A; McLachlan SA; Moore MM
    Med Oncol; 2017 Sep; 34(10):175. PubMed ID: 28879441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.